Adial Pharmaceuticals Inc – Plans of Reorganization, Merger, Acquisition or Similar

NASDAQ: ADIL
Share price (7/22/26): $2.70
Market cap (7/22/26): $5.788 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

from 8-K 128 pages Agreement and Plan of Merger by and Among: Adial Pharmaceuticals, Inc., a Delaware Corporation; Adial Merger Sub I, Inc., a Delaware Corporation; Adial Merger Sub II, LLC, a Delaware Limited Liability Company; and Azora Therapeutics, Inc., a Delaware Corporation Dated as of June 11, 2026

from 8-K 23 pages Final Acquisition Agreement

from 8-K 1 page May 8, 2023 Cary Claiborne Chief Executive Officer Adial Pharmaceuticals, Inc. 1180 Seminole Tr., Ste. 495 Charlottesville, Va 22901 Re: Notice of Option Exercise With Warmest Regards, /S/ William B. Stilley William B. Stilley CEO Agreed: Enclosure /S/ Cary Claiborne Cary Claiborne CEO, Adial Pharmaceuticals, Inc

from 8-K 25 pages Option Agreement for the Acquisition of Purnovate, Inc. by Adenomed, LLC